Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMDW 57 EV-to-FCF is 0.00 as of Sep. 09, 2026. GuruFocus rates BTMDW with a GF Score™ of 57/100. The stock has 2 warning signs investors should review. Among 422 Healthcare Providers & Services companies, Biote ranks better than 73.7% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biote's Enterprise Value is $0.00 Mil.
Biote's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $17.52 Mil. Therefore, Biote's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Biote's EV-to-FCF or its related term are showing as below:
BTMDW'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.9 Med: 6.12 Max: 19.19
Current: 9.61
During the past 7 years, the highest EV-to-FCF of Biote was 19.19. The lowest was -22.90. And the median was 6.12.
BTMDW's EV-to-FCF is ranked better than 73.7% of 422
companies
in the Healthcare Providers & Services industry
Industry Median: 17.455
vs BTMDW: 9.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-09), Biote's stock price is $1.61.
Biote's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.000. Therefore, Biote's PE Ratio (TTM) for today is N/A.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biote's share price for today is $1.61.
Biote's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biote EV-to-FCF Related Terms
Biote EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Biote's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Biote's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biote's EV-to-FCF falls into.
Biote's current Enterprise Value is $0.00 Mil.
Biote's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMDW) has a EV-to-FCF of 0.00 as of Sep. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biote and its competitors. According to the industry distribution chart, Biote ranks #111 out of 422 companies in the Healthcare Providers & Services industry, placing it in the top 26.3%.
Is Biote's EV-to-FCF too high?
Biote's current EV-to-FCF is 0.00. Based on the distribution chart, Biote ranks #111 out of 422 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Biote has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Biote's EV-to-FCF compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #111 out of 422 companies for EV-to-FCF. This puts Biote in the upper half of its industry. The industry median EV-to-FCF is 17.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.46, based on 422 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current EV-to-FCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Biote (BTMDW) has a current EV-to-FCF of 0.00. The current EV-to-FCF is 0.00. Biote's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biote (BTMDW), the current EV-to-FCF is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
57GF Score
Get the complete analysis for BTMDW
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMDW has been successfully added to your 
